Macrolide Regimens for Respiratory Tract Infections

Introduction to Macrolide Therapy

The American Thoracic Society recommends azithromycin 500 mg daily for 3 days or the traditional 5-day regimen for acute respiratory tract infections in adults, while for chronic suppressive therapy in bronchiectasis with ≥3 exacerbations per year, azithromycin 500 mg three times weekly is the preferred regimen with the strongest evidence for reducing exacerbations and improving quality of life 1, 2, 3

The standard azithromycin regimen of 500 mg daily for 3 days is an effective short-course option for upper respiratory infections, leveraging azithromycin's prolonged tissue half-life that maintains therapeutic concentrations for approximately 10 days after the last dose 4

Azithromycin 500 mg three times weekly is the regimen with the strongest evidence base for patients with ≥3 exacerbations per year, demonstrating significant reduction in exacerbations and improvement in quality of life 1, 2, 6, 7
Minimum treatment duration should be at least 6 months to demonstrate benefit in exacerbation reduction 1, 2, 6
Azithromycin 250 mg daily also has high-quality evidence, reducing exacerbations from 2.05 to 0.84 per year 7, 1, 2

ECG is mandatory to assess QTc interval before initiating any macrolide therapy, with a contraindication if QTc >450 ms (men) or >470 ms (women) 6, 8
Baseline liver function tests are required before starting long-term therapy, with follow-up tests at 1 month, then every 6 months 6, 8

Long-term macrolide use increases antimicrobial resistance, though clinical impact remains uncertain, and must be balanced against the significant reduction in exacerbations and improved quality of life in appropriately selected patients 2, 6, 1
Patient selection should only initiate in patients with ≥3 exacerbations per year requiring antibiotics, with optimization of other therapies first and discussion with a respiratory specialist 1, 2, 6, 8